Form PTO 1449 (Modified)			ATTY DOCKET NO. 244288US0DIV		SERIAL NO. 10/6906ラ1					
			·= <b>-</b>	APPLICANT .						
LIST OF	REFE	RENCES CITED BY API	PLICANT	Hiroyuki ISHIWATA, et al.	Hiroyuki ISHIWATA, et al.					
	•			FILING DATE		GROUP				
				Herewith 10/23 /03		1	624			
				U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	· FILING DATE IF APPROPRIATE			
	AA				<u> </u>	'				
	AB				'					
	AC				· '	<u> </u>				
	AD				Ĺ'	<u> </u>				
	AE									
	AF									
	AG					!				
	AH				'					
	Al				'					
	AJ				'					
	AK				[!					
	AL		<u></u>		<u> </u>					
	AM		[	·	'					
	AN		<u> </u>		<u>['</u>	Ĺ				
			FO	PREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY		YES	TRANSLATION S NO			
* BC	AO	1-106818	04/24/89	JAPAN (w/English abstract)			xx			
* Be	AP	7-017506	03/01/95	JAPAN (w/English abstract)			xx			
* BC	AQ.	8-092216	04/09/96	JAPAN (w/English abstract)			xx			
* BC	AR	8-109177	04/30/96	JAPAN (w/English abstract)			xx			
* BC	AS	10-324631	12/08/98	JAPAN (w/English abstract)			xx			
* BC	AT	11-269192	10/05/99	JAPAN (w/English abstract)			xx			
* BC	AU	59-167564	09/21/84	JAPAN (w/English abstract)			xx			
* BC	AV	WO 96/11682	1996	WIPO (corr. EP 0 787 491)						
		OTHER RE	FERENCES (	Including Author, Title, Date, Pertinent	Pages, e	tć.)				
				sis and cardiovascular properties of 5-(4-p			5-(4-pyridinyl)- and 6-			
	AW	methyl 5-phenyl -subst	ituted 3-cyano	2-2-aminoalkylaminopyridines, Pharmazie	45: 240-2	41, 1990.	• • •			
BC	AX	Robert B. Fick, Jr., Current Opinion in Pulmonary Medicine, vol. 5, pages 76-80, "ANTI-IgE AS NOVEL THERAPY FOR THE TREATMENT OF ASTHMA", 1999.								
BC	AY	Farhad Imani, Emerging Therapeutic Targets, vol. 3, no. 2, pages 229-240, "EMERGING THERAPEUTIC TARGETS IN ASTHMA AND ALLERGY: MODULATION OF IgE", 1999.								
BC	AZ	pages 1966-1973, "TRI	t al., The New England Journal of Medicine, vol. 341, no. 26, 3, "TREATMENT OF ALLERGIC ASTHMA WITH ANTI-IgE ANTIBODY", December 23, 1999.							
Examiner	び	renda (	Colem	$\subset$	Date Con	sidered f	JOG F lingt			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

Form PTO 1449 (Modified)		U.S. DEPARTMENT PATENT AND TRAC		ATTY DOCKET NO. 244288US0DIV		SERIAL NO. 10/690671				
· 				APPLICANT						
LIST OF	REFE	RENCES CITED BY AP	PLICANT	·Hiroyuki ISHIWATA, et al.						
				FILING DATE HEREWITH 10/23/03		GROUP				
						1624				
				U.S. PATENT DOCUMENTS		•				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE			
	AAA									
	AAB			·						
	AAC				<u> </u>					
	AAD									
	AAE									
	AAF									
•	AAG		<u> </u>							
	AAH									
	AAI									
	AAJ				<u> </u>					
	AAK						<u> </u>			
•	AAL									
	AAM									
	AAN	<u> </u>		·	<u> </u>					
•		·	FO	REIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	COUNTRY		TRANSLATION NO			
BC	AAO	0 787 491	08/06/97	EUROPE		·				
* BC	AAP	WO 98/04508	02/05/98	WIPO (w/English abstract)			xx			
x BC	AAQ	WO 98/07702	02/26/98	WIPO (w/English abstract)			xx			
* BC	AAR	WO 98/16497	04/23/98	WIPO (w/English abstract)			xx			
x BC	AAS	WO 99/19291	04/22/99	WIPO (w/English abstract)			xx			
* BC	AAT	WO 99/35140	07/15/99	WIPO						
$*\beta c$	AAU	WO 99/38829	08/05/99 ·	WIPO (w/English abstract)			××			
* BC	AAV	WO 99/42446	08/26/99	WIPO (w/English abstract)			ж			
r BC	AAW	WO 00/05198	02/03/00	WIPO (w/English abstract)			xx			
		OTHER RE	FERENCES (I	including Author, Title, Date, Pertinent	Pages, et	tc.)				
BC	AAX	Naosuke Matsuura, et al., Jpn. Pharmacol. Ther., vol. 22, no. 3, pages 1369-1383, "AN IMMUNOPHARMACOLOGICAL STUDY OF (±) - [2- [4-(3-ETHOXY-2-HYDROXYPROPOXY) PHENYLCARBAMOYL] ETHYL] DIMETHYLSULFONIUM P-TOLUENESULFONATE (SUPLATAST TOSILATE, IPD-1151T)", 1994.								
	AAY					•				
	AAZ			•	Addit	ional Refe	rences sheet(s) attached			
Examiner Brenda Coleman Date Considered April 7, 20							2006, Fliraf			
*Examiner: In conformance	itial if re and no	eference is considered, toonsidered. Include co	whether or not py of this form	citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw lin	e through	citation if not in			



## **LIST OF RELATED CASES**

**Docket Number** 

244288US0-DIV\*

Serial or Patent Number 10/690,671

Filing or Issue Date 10/23/03

Inventor/ **Applicant** ISHIWATA, et al.

**6** 208671US0

09/893,680

06/29/01

ISHIWATA, et

al.